Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scilex Holding CoSCLX · Entity 7345 | Director · See Remarks | December 18, 2024 | December 18, 2024 |
| Semnur Pharmaceuticals, Inc.SMNR · Entity 6623 | Director · See Remarks | September 22, 2025 | September 23, 2025 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | Director | August 30, 2021 | August 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scilex Holding Co
Report date December 18, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,333 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Purchase · Acquired 30,000 · Balance 139,333 F1: Open market purchase by the Reporting Person of 30,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices. F2: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on December 18, 2024 at prices ranging from $0.4590 to $0.4600 per share, inclusive. The amount reflected has been rounded to four decimal points. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 155,882 |
Reported balance
Holding disclosure · report date 2024-12-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 155,882 F3: Shares are held in a family trust of which the Reporting Person is a co-trustee with his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase by the Reporting Person of 30,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices.
F2: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on December 18, 2024 at prices ranging from $0.4590 to $0.4600 per share, inclusive. The amount reflected has been rounded to four decimal points. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range.
F3: Shares are held in a family trust of which the Reporting Person is a co-trustee with his spouse.
Semnur Pharmaceuticals, Inc.
Report date September 22, 2025 · Filed September 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2034-08-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-09-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The option vests in equal monthly installments of 1/48th per month. Except as described in the next sentence, the option is currently exercisable pursuant to the approval by shareholders of the Issuer of the option exchange on September 3, 2025, as described in the Issuer's Registration Statement on Form S-4 filed with the Securities and Exchange Commission (File No. 333-283019), which became effective on August 12, 2025. Until the date on which all payments and all obligations under that certain Senior Secured Promissory Note, dated as of September 21, 2023, issued by Scilex Holding Company (the controlling stockholder of the Issuer) to Oramed Pharmaceuticals, Inc., a Delaware corporation, have been paid in full in cash, the options will not be or become exercisable, F2: (Continued from footnote 1) eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Issuer or any of its respective current and future subsidiaries, successors and assigns. F3: The option expires ten years from the date of issuance, unless earlier terminated in accordance with the terms of the Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan. F4: Represents shares of the Issuer's Common Stock underlying the option, for which (except as described above) the option became exercisable in connection with a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, a wholly owned subsidiary of the Issuer, and Semnur, Inc. (f/k/a Semnur Pharmaceuticals, Inc.) ("Old Semnur"), which became a wholly owned subsidiary of the Issuer upon completion of the Business Combination. Upon consummation of the Business Combination, the reporting person's option to purchase shares of common stock of Old Semnur was exchanged for an option to purchase shares of common stock of the Issuer at an exchange ratio of 1.25 to 1. The number of shares reflects the application of the exchange ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments of 1/48th per month. Except as described in the next sentence, the option is currently exercisable pursuant to the approval by shareholders of the Issuer of the option exchange on September 3, 2025, as described in the Issuer's Registration Statement on Form S-4 filed with the Securities and Exchange Commission (File No. 333-283019), which became effective on August 12, 2025. Until the date on which all payments and all obligations under that certain Senior Secured Promissory Note, dated as of September 21, 2023, issued by Scilex Holding Company (the controlling stockholder of the Issuer) to Oramed Pharmaceuticals, Inc., a Delaware corporation, have been paid in full in cash, the options will not be or become exercisable,
F2: (Continued from footnote 1) eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Issuer or any of its respective current and future subsidiaries, successors and assigns.
F3: The option expires ten years from the date of issuance, unless earlier terminated in accordance with the terms of the Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan.
F4: Represents shares of the Issuer's Common Stock underlying the option, for which (except as described above) the option became exercisable in connection with a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, a wholly owned subsidiary of the Issuer, and Semnur, Inc. (f/k/a Semnur Pharmaceuticals, Inc.) ("Old Semnur"), which became a wholly owned subsidiary of the Issuer upon completion of the Business Combination. Upon consummation of the Business Combination, the reporting person's option to purchase shares of common stock of Old Semnur was exchanged for an option to purchase shares of common stock of the Issuer at an exchange ratio of 1.25 to 1. The number of shares reflects the application of the exchange ratio.
Sorrento Therapeutics, Inc.
Report date August 30, 2021 · Filed August 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.86 · Expires 2031-08-30 | Direct | 250,000 |
Reported balance
After 2021-08-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-30 · Grant · Acquired 250,000 · Balance 250,000 F1: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2024 Filed Dec 18, 2024 19:04 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 30,000 | $0.46 | $13,800.00 |
DisclosureSEC source: 0000950170-24-138066 · ownership.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,333 F1 · kind: Open market purchase by the Reporting Person of 30,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices. F2 · price: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on December 18, 2024 at prices ranging from $0.4590 to $0.4600 per share, inclusive. The amount reflected has been rounded to four decimal points. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range. Read SEC document |
| October 29, 2024 Filed Oct 29, 2024 18:59 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 32,000 | $0.99 | $31,670.40 |
DisclosureSEC source: 0000950170-24-118435 · ownership.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,333 F1 · kind: Open market purchase by the reporting person of 32,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions at a price of $0.9897. F2 · price: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on October 29, 2024 at a price of $0.9897. The amount reflected has been rounded to four decimal points. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 12:44 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 30,000 | $0.99 | $29,751.00 |
DisclosureSEC source: 0000950170-24-115226 · ownership.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,333 F1 · kind: Open market purchase by the reporting person of 30,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices. F2 · price: Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on October 16, 2024 at prices ranging from $0.9674 to $1.0000 per share, inclusive. The amount reflected has been rounded to four decimal points. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 16:43 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionNonstatutory Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0000950170-24-075656 · ownership.xml · derivative · entry 3 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,880,598 Underlying: Common Stock · 14,000 shares Expires 2029-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the original number of shares subject to the option vested on March 18, 2020, and 1/36th of the remaining number of shares subject to the option vested and shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 16:43 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionCommon Stock | 14,000 | $1.73 | $24,220.00 |
DisclosureSEC source: 0000950170-24-075656 · ownership.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 1/4th of the original number of shares subject to the option vested on March 18, 2020, and 1/36th of the remaining number of shares subject to the option vested and shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:02 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionNonstatutory Stock Option (right to buy) · Derivative | 33,333 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-24-073618 · ownership.xml · derivative · entry 3 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 33,333 shares Expires 2033-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:02 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionCommon Stock | 33,333 | $1.41 | $46,999.53 |
DisclosureSEC source: 0000950170-24-073618 · ownership.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| May 17, 2024 Filed May 17, 2024 17:36 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 56,939 | $0.92 | $52,099.19 |
DisclosureSEC source: 0000950170-24-061928 · ownership.xml · nonDerivative · entry 2 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 155,882 F2 · shares: Open market purchase by the reporting person of 56,939 shares of Common Stock. F3 · ownership.nature: Shares are held in a family trust of which the reporting person is a co-trustee with his spouse. Read SEC document |
| May 16, 2024 Filed May 17, 2024 17:36 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 83,061 | $0.84 | $69,845.99 |
DisclosureSEC source: 0000950170-24-061928 · ownership.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 98,943 F1 · shares: Open market purchase by the reporting person of 83,061 shares of common stock, par value $0.0001 per share (the "Common Stock"). F3 · ownership.nature: Shares are held in a family trust of which the reporting person is a co-trustee with his spouse. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 21:28 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-23-052257 · ownership.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-10-04 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 17:23 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 1,700,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0000899243-23-001869 · doc4.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,000 Underlying: Common Stock · 1,700,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date. Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:14 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001209191-21-053984 · doc4.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-08-30 F1 · derivative.exercise_date: 1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 18:10 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0000850261-20-000046 · wf-form4_159225902613694.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: 1/12th of the original number of shares subject to this option shall vest and become exercisable on July 15, 2020, and 1/12th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 21:03 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 70,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000850261-19-000016 · wf-form4_155606780056621.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-04-19 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable on May 14, 2019 and following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 19:48 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000850261-18-000044 · wf-form4_154336608310581.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-11-26 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date. Read SEC document |
| September 15, 2017 Filed Sep 15, 2017 21:44 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001144204-17-048358 · v475324_4.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-15 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 06:14 UTC Amendment | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-048372 · v475336_4a.xml · derivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-15 F1 · derivative.exercise_price: This amended report on Form 4 is being filed to amend the Form 4 filed by the reporting person on September 15, 2017 to correct the exercise price, which was inadvertently reported as $1.75. F2 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 16:13 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | PurchaseCommon Stock | 10,002 | $1.79 | $17,903.58 |
DisclosureSEC source: 0001144204-17-032723 · v469082_4.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,633 Read SEC document |
| February 03, 2017 Filed Feb 3, 2017 19:44 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | PurchaseCommon Stock | 10,000 | $5.15 | $51,500.00 |
DisclosureSEC source: 0000899243-17-002779 · doc4.xml · nonDerivative · entry 1 SHAH JAISIM · CIK 0001242133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,631 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.